CSPC Pharmaceutical Group Limited

As of June 30, 2026, CSPC Pharmaceutical Group Limited carries a market capitalization of 79.50B, placing it among publicly traded companies globally. Its enterprise value stands at 60.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CSPC Pharmaceutical Group Limited's next confirmed earnings release is scheduled for March 24, 2027.

As of June 30, 2026, CSPC Pharmaceutical Group Limited has 11.41B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CSPC Pharmaceutical Group Limited maintains a current ratio of 2.14, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, CSPC Pharmaceutical Group Limited's stock has declined approximately 1.24% over the past 52 weeks. The 50-day moving average sits at 9.21, while the 200-day moving average is 8.78.

As of June 30, 2026, CSPC Pharmaceutical Group Limited holds 21.44B in cash and equivalents against 754.14M in total debt, resulting in a net debt position of -11.09B. Total book value stands at 43.49B, with working capital of 18.99B providing operational flexibility.

CSPC Pharmaceutical Group Limited's most recent stock split took place on October 15, 2020 with a 5:8 split ratio.